USPTO 2015–2025 USPTO PatentsView US Corporation

Xenoport, Inc.

USPTO PatentsView assignee record - 20 granted patents across 6 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Xenoport ranks #15,060 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 6 technology areas.

#15,060
of 49,997 US assignees by volume
28th percentile
by Innovation Score (28.8/100)
15.9
avg claims per patent
-100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15060 · US Corporation #15,060 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-SMALL 20 grants
  • MID-PACK #15,060/49,997
  • PHOTO-FINISH Wellis USA
  • CPC-NARROW A61P · 6 areas
  • INNOV-THIN 28.8/100
  • CLAIMS-RICH 15.9 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Wellis USA Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Xenoport’s 28.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Xenoport

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Xenoport's Innovation Score is 28.8/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Xenoport?

Each dot is one of Xenoport’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Xenoport’s own 15.9 claims/patent is ABOVE the 15.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Xenoport vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 19.919.92020.1 010203040 Granted patents (volume) Avg claims / patent Wellis USA Inc. - 20, 1Wellis USAWerlatone, Inc. - 20, 17WerlatoneWillow Garage, LLC - 20, 20.7Willow GarageWillow Laboratories, Inc. - 20, 15.65Willow Laboratori…Xi'an Novastar Tech Co., Ltd. - 20, 12.1Xi'an Novastar Te…Xjet Ltd. - 20, 14.6XjetXiros Limited - 20, 31.15XirosXtone, Inc. - 20, 27.35XtoneXenoport, Inc. - 20, 15.95Xenoport
Xenoport vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Xenoport's grants concentrate

Xenoport, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 90% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (8 grants) versus a trough of 3 in 2015. By volume, Xenoport sits between Wellis USA Inc. and Xtone, Inc..

Who files at Xenoport's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Xenoport holds 20 patents at rank #15,053, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Xenoport

By rank, the assignees closest to #15,053 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Xenoport's primary technology class.

Xenoport's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

246810 2015201620172018 5
USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Xenoport, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 3 15.0%
2016 8 40.0%
2017 4 20.0%
2018 5 25.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Xenoport, Inc.'s patent record in context - here's where to go next.

  • Xenoport, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 90% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #15,060 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Xenoport, Inc. against Wellis USA Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 28.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.